

OBN Investment & Tax Special Interest Group (ITSIG)

The OBN Investment & Tax Special Interest Group (ITSIG) works hard to get the voice of its members heard in the national and local political arena in an effort to create a more favourable fiscal environment for emerging, small and medium sized enterprises in the life sciences industry from UK and European Governments.

Established in 2014, the OBN Investment & Tax Special Interest Group is chaired by **Shawn Manning**, Managing Director, Akesios Associates Limited. He is joined by:

Stuart Rose, CEO, OBN

Bill Fleming, CFO, IngenOx Therapeutics

Matthew Frohn, Partner, Longwall Ventures

Kathy Hills, Partner – Corporate Tax, Penningtons Manches Cooper

Helen Kuhlman, CBO, Evgen Pharma

Howard Sherman, CFO, Safeguard Biosystems Holdings Ltd

Mike Shearan, Senior Manager, James Cowper Kreston

Graham Samuel-Gibbon, Partner, Taylor Wessing

The objectives of the Group are to:

- 1. Define and Evolve Policy on Behalf of OBN and its Members:** Help to create and define/evolve policy in relation to the OBN position on matters relating to investment, grant funding and taxation¹ as they affect member companies and the UK, and where relevant, other Health Economies.
- 2. Advise and Support Life Science Advocates on Issues Impacting Members:** Advise and support life science advocates² on matters relating to investment, grant funding and taxation as they affect member companies and the UK Health Economy.
- 3. Direct Advocacy to Support Members' Interests:** On occasion and where appropriate, act as direct advocates on behalf of OBN, for policy where the group as a whole, or individual members, have specific expertise or experience that will enhance the membership's interests.
- 4. Support OBN Consultation with, and Notification to, its Membership on Relevant Issues:** Support³ OBN's periodic consultations, surveys and outcome notifications⁴ with the membership regarding issues related to ITSIG's areas of expertise.

¹ Including but not limited to EIS, SEIS, 'Patent Box' and R&D tax credits

² Including, but not limited to the BIA, ABPI and the OLS

³ Where appropriate, and with the condition that this support is not detrimental to the effectiveness of the SIG in terms of objectives 1,2,and 3

⁴ Including, but not limited to, policy positions and policy 'wins' with respect to our impact on decision making